---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046067"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:50:28.910085+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track

## Summary
- Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.
- Q4 2024 net loss $44.1M ($0.84/sh) vs $59.5M ($1.13/sh) in Q4 2023; R&D expenses $31.8M.
- Tarcocimab Phase 3 GLOW2 (diabetic retinopathy) enrollment complete; topline data targeted 1Q2026.
- Tarcocimab & KSI-501 Phase 3 DAYBREAK (wet AMD) enrollment complete; topline data targeted 2Q2026.
- KSI-101 granted FDA Orphan Drug Designation; pivotal study initiation expected 2Q2025.

## SEC filing metadata
- accession: 0000950170-25-046067
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/0000950170-25-046067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/kod-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046067
- JSON: https://secwatch.observer/filing/0000950170-25-046067.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.